Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
63
SNYNF Quote, Financials, Valuation and Earnings
Last price:
$96.76
Seasonality move
:
4.45%
Day range:
$94.53 - $96.02
52-week range:
$90.05 - $122.03
Dividend yield:
4.53%
P/E ratio:
20.11x
P/S ratio:
2.37x
P/B ratio:
1.48x
Volume:
371
Avg. volume:
66.1K
1-year change:
-14.27%
Market cap:
$115.9B
Revenue:
$49.2B
EPS (TTM):
$4.78
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sanofi has 33.5% upside to fair value with a price target of -- per share.
SNYNF vs. S&P 500
-
Over the past 5 trading days, Sanofi has overperformed the S&P 500 by 2.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sanofi does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sanofi has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Sanofi reported revenues of $12.2B.
Earnings Growth
-
Sanofi has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Sanofi reported earnings per share of $3.65.
Enterprise value:
125.2B
EV / Invested capital:
--
Price / LTM sales:
2.37x
EV / EBIT:
9.71x
EV / Revenue:
2.53x
PEG ratio (5yr expected):
7.24x
EV / Free cash flow:
15.05x
Price / Operating cash flow:
14.09x
Enterprise value / EBITDA:
6.44x
Gross Profit (TTM):
$32.6B
Return On Assets:
7.11%
Net Income Margin (TTM):
11.31%
Return On Equity:
12.45%
Return On Invested Capital:
9.89%
Operating Margin:
15.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $45.3B | $44.6B | $43.2B | $10.9B | $12.2B | |
| Gross Profit | $28.5B | $27.4B | $28.3B | $7.7B | $8.8B | |
| Operating Income | $10.2B | $9.3B | $10.8B | $1.9B | $1.9B | |
| EBITDA | $13.9B | $13.9B | $15.1B | $2B | $2.1B | |
| Diluted EPS | $7.13 | $3.63 | $5.62 | $0.96 | $3.65 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34.7B | $36.6B | $33.9B | $44.3B | -- | |
| Total Assets | $136.1B | $135.9B | $139.8B | $138.2B | -- | |
| Current Liabilities | $24.1B | $25.7B | $26.8B | $30.3B | -- | |
| Total Liabilities | $58B | $55.3B | $57.6B | $57.2B | -- | |
| Total Equity | $78.2B | $80.6B | $82.2B | $81B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.6B | $8.8B | $12.2B | $1.4B | $1.8B | |
| Cash From Investing | -$3.9B | -$7.1B | $8.4B | -$3.3B | $10.7B | |
| Cash From Financing | -$5.8B | -$3B | -$11.2B | -$729.7M | -$4.5B | |
| Free Cash Flow | $8.2B | $4.5B | $9.2B | -$506.9M | $218.7M | |
SNYNF
Sector
Market Cap
$115.9B
$25.8M
Price % of 52-Week High
78.69%
50.24%
Dividend Yield
4.53%
0%
Shareholder Yield
9.29%
-1.64%
1-Year Price Total Return
-14.27%
-18.88%
Beta (5-Year)
0.241
0.496
Dividend yield:
4.53%
Annualized payout:
$4.35
Payout ratio:
-76.86%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$94.34
200-day SMA
Sell
Level
$97.37
Bollinger Bands (100)
Sell
Level
94.11 - 100.11
Chaikin Money Flow
Sell
Level
-223.7K
20-day SMA
Buy
Level
$94.45
Relative Strength Index (RSI14)
Buy
Level
54.13
ADX Line
Buy
Level
16.61
Williams %R
Neutral
Level
-30.5761
50-day SMA
Buy
Level
$94.94
MACD (12, 26)
Buy
Level
25.93
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-221.8K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4675)
Buy
CA Score
(Annual)
Level (0.4078)
Buy
Beneish M-Score
(Annual)
Level (-2.7687)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-2.1734)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.
Stock Forecast FAQ
In the current month, SNYNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNYNF average analyst price target in the past 3 months is --.
-
Where Will Sanofi Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sanofi share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sanofi?
Analysts are divided on their view about Sanofi share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sanofi is a Sell and believe this share price will drop from its current level to --.
-
What Is Sanofi's Price Target?
The price target for Sanofi over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNYNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sanofi is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SNYNF?
You can purchase shares of Sanofi via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sanofi shares.
-
What Is The Sanofi Share Price Today?
Sanofi was last trading at $96.76 per share. This represents the most recent stock quote for Sanofi. Yesterday, Sanofi closed at $96.02 per share.
-
How To Buy Sanofi Stock Online?
In order to purchase Sanofi stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SNYNF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SNYNF
Sector
P/E ratio
20.11x
23.44x
PEG ratio
7.24x
-0.01x
P/B ratio
1.48x
1.81x
Price / LTM sales
2.37x
1.56x
Growth Metrics
SNYNF
Sector
Revenue growth
11.24%
3.27%
Earnings growth
281.16%
9.66%
Revenue (5-year growth)
3.69%
6.43%
Earnings forecast
--
-$0.20
Profitability
SNYNF
Sector
Profitability FY 2025
$32.3B
$2.3M
Return on invested capital
9.89%
-33.49%
Return on assets
7.11%
-29.74%
Return on equity
12.45%
-39.33%
Earnings Date
Last Earnings Date
Jan
29
Next Earnings Date
Apr
23
Estimated Next Earnings Date
Apr
30
Balance Sheet
SNYNF
Sector
Total cash
$18B
$24.2M
Short term investments
$505.7M
$23.8M
Total assets
$148.9B
$71.1M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 8.34% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 8.09% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.58% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
